Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7688 clinical trials
TPM Regimen (Thalidomide Prednisone and Methotrexate) in LGLL

Large granular lymphocytic leukemia (LGLL) is a lymphoproliferative disease, with LGL infiltration in peripheral blood and bone marrow, hepatosplenomegaly, and cytopenia.

clpd-nk
lymphoproliferative disorder
hepatosplenomegaly
cytopenia
large granular lymphocytic leukemia
  • 0 views
  • 19 Feb, 2024
  • 9 locations
CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

In this protocol, the investigators hypothesize that modifying the process of producing CAR+ T-cells can help to improve responses and reduce toxicities. Building on previous in vitro studies that have shown successful production of CAR+ T-cells using a new production approach, the investigators are now studying the ability to produce …

b-cell lymphoma
systemic disease
immediate hypersensitivity reaction
measurable disease
alt/ast
  • 0 views
  • 19 Feb, 2024
  • 1 location
Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

This phase II trial studies how well decitabine with ruxolitinib or fedratinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors). Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, …

myelofibrosis
myeloproliferative/myelodysplastic disorders
cancer care
ruxolitinib
cancer
  • 0 views
  • 19 Feb, 2024
  • 1 location
Brief Title: Study of BGB-10188 as Monotherapy and in Combination With Zanubrutinib and Tislelizumab

The purpose of this study is to determine the maximum tolerated dose (MTD), recommended Phase 2 dose(RP2D),safety & tolerability of BGB-10188: as monotherapy in participants with mature B-cell malignancies; oin combination with zanubrutinib in participants with relapse/refractory follicular lymphoma (R/R FL), mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma …

cancer, ovarian
b-cell lymphoma
solid tumors
small cell lung cancer
cancer
  • 0 views
  • 19 Feb, 2024
  • 4 locations
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this …

absolute neutrophil count
ibrutinib
waldenstrom's macroglobulinemia
venetoclax
plasmapheresis
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Molecular Diagnostic Platform for AML

This will be a translational study without any therapeutic intervention, for the purpose of analyzing the diagnostic and molecular results / characterization of adult patients with AML, regardless of the treatment they receive. Newly diagnosed or relapsed/resistant AML patients will be included.

  • 0 views
  • 19 Feb, 2024
  • 7 locations
InO - A Retrospective Study of UK Patients With Leukaemia

The purpose of this study is to describe the demographics and clinical characteristics, treatment pathway, and effectiveness and safety of inotuzumab ozogamicin in patients with relapsed/refractory B-cell acute lymphoblastic leukaemia treated with inotuzumab ozogamicin in the real-world.

acute lymphoblastic leukemia
inotuzumab
lymphoblastic leukemia
lymphoma
leukemia
  • 0 views
  • 19 Feb, 2024
  • 3 locations
Advanced Translational Research on Childhood Leukemia

Prognosis of children with leukemia, the most common pediatric cancer, has improved markedly. Yet, relapse still occurs in 15-40% of patients with a probability of survival of <50%, which is unlikely to be boosted by intensification of standard chemotherapy due to overwhelming toxicity.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation

Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well Venetoclax works to treat AML in adult participants who are ineligible for standard induction therapy in Russian Federation.

  • 0 views
  • 19 Feb, 2024
  • 3 locations